静脉注射白消安加美法仑与单独使用美法仑作为多发性骨髓瘤患者的预处理方案比较。 - Suppr | 超能文献

相似文献

1

Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma.静脉注射白消安加美法仑与单独使用美法仑作为多发性骨髓瘤患者的预处理方案比较。

Ann Hematol. 2019 Aug;98(8):2013-2015. doi: 10.1007/s00277-019-03663-5. Epub 2019 Mar 16.

2

Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150).多骨髓瘤患者自体干细胞移植用静脉注射白消安和马法兰预处理方案的 2 期研究（KMM150）。

Biol Blood Marrow Transplant. 2018 May;24(5):923-929. doi: 10.1016/j.bbmt.2018.01.004. Epub 2018 Jan 12.

3

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.在多发性骨髓瘤自体造血细胞移植前，白消安加美法仑与单用美法仑进行预处理的比较：一项开放标签、随机、3期试验。

Lancet Haematol. 2019 May;6(5):e266-e275. doi: 10.1016/S2352-3026(19)30023-7. Epub 2019 Mar 22.

4

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.白消安、美法仑和硼替佐米与大剂量美法仑作为多发性骨髓瘤自体造血干细胞移植预处理方案的比较

Biol Blood Marrow Transplant. 2016 Aug;22(8):1391-1396. doi: 10.1016/j.bbmt.2016.03.021. Epub 2016 May 7.

5

Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.静脉注射白消安和马法兰作为新诊断多发性骨髓瘤患者自体干细胞移植的预处理方案：与仅用马法兰方案的匹配比较。

Biol Blood Marrow Transplant. 2013 Jan;19(1):69-74. doi: 10.1016/j.bbmt.2012.08.009. Epub 2012 Aug 13.

6

Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.静脉注射白消安联合马法兰是一种高效、耐受性良好的用于治疗晚期淋巴系统恶性肿瘤的自体干细胞移植预处理方案。

Biol Blood Marrow Transplant. 2011 Mar;17(3):412-20. doi: 10.1016/j.bbmt.2010.07.016. Epub 2010 Jul 30.

7

Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma.美法仑与美法仑加白消安用于低危多发性骨髓瘤自体干细胞移植预处理的比较

Hematol J. 2004;5(2):118-22. doi: 10.1038/sj.thj.6200369.

8

Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.在 PETHEMA/GEM2000 研究中，对于新诊断的多发性骨髓瘤患者进行自体移植，采用马法兰 12mg/kg 加白消安 140mg/m2 或马法兰 200mg/m2 作为预处理方案。

Haematologica. 2010 Nov;95(11):1913-20. doi: 10.3324/haematol.2010.028027. Epub 2010 Jul 27.

9

Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma.药代动力学导向的静脉注射白消安联合大剂量美法仑和硼替佐米作为多发性骨髓瘤患者的预处理方案

Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):650-657. doi: 10.1016/j.clml.2017.06.005. Epub 2017 Jun 17.

10

[Busulfan, cyclophosphamide and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma].白消安、环磷酰胺和依托泊苷作为多发性骨髓瘤自体干细胞移植的预处理方案

Zhonghua Xue Ye Xue Za Zhi. 2013 Apr;34(4):313-6. doi: 10.3760/cma.j.issn.0253-2727.2013.04.014.

引用本文的文献

1

Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation.培非格司亭生物类似药在接受大剂量美法仑和自体造血干细胞移植后的多发性骨髓瘤患者中的疗效。

Ann Hematol. 2023 Jul;102(7):1915-1925. doi: 10.1007/s00277-023-05228-z. Epub 2023 Apr 20.

2

Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2022. Part I.多发性骨髓瘤治疗的诊断与管理指南：巴西血液学、血液治疗与细胞治疗协会项目指南：巴西医学协会 - 2022年。第一部分。

Hematol Transfus Cell Ther. 2022 Jul-Sep;44(3):410-418. doi: 10.1016/j.htct.2022.06.003. Epub 2022 Jul 20.

3